Prevalence of Pretreatment Testing Recommended for Patients With Chronic Inflammatory Skin Diseases.

ABSTRACT:

Importance

Laboratory testing for the presence of tuberculosis, hepatitis, and other conditions before starting most systemic immunomodulatory agents is recommended in patients with chronic inflammatory skin diseases (CISD) but current testing patterns in the US are unclear.

Objective

To determine the prevalence of pretreatment testing that is recommended for patients with CISD (psoriasis, hidradenitis suppurativa, or atopic dermatitis).

Design, setting, and participants

This descriptive analysis of US commercial insurance claims databases from December 31, 2002, to December 31, 2020, included adult patients with CISD (psoriasis, hidradenitis suppurativa, or atopic dermatitis) who started an immunomodulatory agent, including methotrexate, tumor necrosis factor α inhib

SUBMITTER: Schneeweiss MC 

PROVIDER: S-EPMC10831628 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature